Home > Cardiology > ESC 2021 > EMPORER-Preserved: Interview with Prof. Stefan Anker

EMPORER-Preserved: Interview with Prof. Stefan Anker

Principal Investigator
Prof. Stefan Anker
Conference
ESC 2021
Trial
EMPEROR-Preserved
Medicom: Thank you so much for joining us, Professor Anker. Can you tell me a little bit about the significance of the results presented at the European Society of Cardiology with regard to the EMPEROR-Preserved trial? Prof. Anker: Thank you so much for the question about EMPEROR-Preserved, which is the first positive trial with clinical trial results that are really meaningful for patients in heart failure with preserved ejection fraction. Now we all know that SGLT2 inhibitors work in heart failure with reduced ejection fraction, less than 20%, which has been reported over the last one or two years from several trials. Now, we are focusing on heart failure with preserved ejection fraction, where the current guidelines and new guidelines actual...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on